Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers
- 28 September 2007
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (10) , 3236-3247
Abstract
Objective: To evaluate the performance of biochemical and traditional markers in predicting radiographic progression in rheumatoid arthritis (RA).Methods: One hundred thirty‐two patients with early RA were treated with nonbiologic therapies for 2 years and studied longitudinally. Genomic DNA was analyzed for presence of the shared epitope. Levels of matrix metalloproteinases (matrix metalloproteinase 1 [MMP‐1], MMP‐13, and MMP‐3), tissue inhibitor of metalloproteinases 1 (TIMP‐1), and cartilage oligomeric matrix protein (COMP) were assessed in serially obtained serum samples. The presence of pyridinoline (Pyr), deoxypyridinoline, glycosylated Pyr (Glc‐Gal‐Pyr), and C‐telopeptide of type II collagen (CTX‐II) was assessed in urine samples. Radiographs obtained at entry and at 2 years were evaluated using the modified Larsen score.Results: Baseline and 2‐year radiographs were available from 118 patients. Larsen scores worsened during the 2 years in 50 patients, while 68 patients had no radiographic progression. Levels of a variety of biochemical markers, i.e., MMP‐3, CTX‐II, COMP, TIMP‐1, Pyr, and Glc‐Gal‐Pyr, correlated significantly with radiographic progression at entry and longitudinally as assessed by area under the curve (AUC). By multivariate analysis, a model including MMP‐3 and CTX‐II was identified as providing the best prediction of radiographic progression at entry (predictive accuracy by receiver operating characteristic [ROC] AUC = 0.76 [95% confidence interval 0.66–0.85]), while a combination of MMP‐3, CTX‐II, and swollen joint count formed the best longitudinal AUC model (predictive accuracy by ROC AUC = 0.81 [95% confidence interval 0.73–0.89]). Patient‐reported measures (Health Assessment Questionnaire, pain scores) were of limited use. In a subset of 50 patients who were treated with methotrexate (MTX) during the followup period, median serum MMP‐3 levels decreased after the initiation of MTX therapy (P =0.0003).Conclusion: These results indicate that biochemical markers are useful predictors of radiographic progression in RA and that serum MMP‐3 levels decrease significantly with MTX therapy. Multivariate models that include MMP‐3 and CTX‐II perform better than existing traditional markers in predicting radiographic outcome in RA.Keywords
This publication has 47 references indexed in Scilit:
- The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritisCytokine, 2006
- Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritisArthritis & Rheumatism, 2005
- Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal studyRheumatology, 2005
- Uncoupling of inflammation and destruction in rheumatoid arthritis: Myth or reality?Arthritis & Rheumatism, 2005
- Development and Validation of Response Criteria in Rheumatoid Arthritis: Steps Towards an International Consensus on Prognostic MarkersRheumatology, 1996
- Levels of circulating collagenase, stromelysin‐1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis: relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammationArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- Analysis of serial measurements in medical research.BMJ, 1990
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980